دورية أكاديمية
أعرض في EDS

Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.

التفاصيل البيبلوغرافية
العنوان: Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
المؤلفون: Friend BD; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. bdfriend@texaschildrens.org., Muhsen IN; Department of Medicine, Houston Methodist Hospital, Houston, TX, USA., Patel S; Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Ramos CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Pingali SR; Houston Methodist Cancer Center, Houston, TX, USA., Kamble RT; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., John TD; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Salem B; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Bhar S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Doherty EE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Craddock J; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Sasa G; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Wu M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Wang T; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Martinez C; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Krance RA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA., Carrum G; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA.
المصدر: Bone marrow transplantation [Bone Marrow Transplant] 2022 Apr; Vol. 57 (4), pp. 579-585. Date of Electronic Publication: 2022 Feb 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: London : Nature Publishing Group
Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986-
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation* , Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology, Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Carmustine/therapeutic use ; Child ; Cytarabine ; Humans ; Melphalan ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Rituximab/therapeutic use ; Transplantation Conditioning ; Transplantation, Autologous ; Young Adult
مستخلص: While high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) leads to improved disease-free survival (DFS) for children and adults with relapsed/refractory Hodgkin lymphoma (HL), relapse remains the most frequent cause of mortality post-transplant. Rituximab has been successfully incorporated into regimens for other B-cell lymphomas, yet there have been limited studies of rituximab in HL patients. We hypothesized that adding rituximab to BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning would reduce relapse risk in HL patients post-transplant. Here, we retrospectively review the outcomes of patients with relapsed/refractory HL who received rituximab in addition to BEAM. The primary outcome was DFS. Our cohort included 96 patients with a median age of 28 years (range, 6-76). Majority of patients (57%) were diagnosed with advanced (Stage III-IV) disease, and 62% were PET negative pre-transplant. DFS was 91.5% at 1 year [95% CI 86-98%], and 78% at 3 years [95% CI 68-88%]. NRM was 0% and 3.5% at 1-year [95% CI 0-3%] and 3-years [95% CI 0-8.5%], respectively. 25% of patients developed delayed neutropenia, with 7% requiring infection-related hospitalizations, and one death. We have demonstrated excellent outcomes for patients receiving rituximab with BEAM conditioning for relapsed/refractory HL. Future comparative studies are needed to better determine whether rituximab augments outcomes post-transplant.
(© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
References: Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS. et al. The treatment of progressive non-Hodgkin’s lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood. 1990;75:831–8. (PMID: 230245610.1182/blood.V75.4.831.831)
Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS. et al. Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086–92. (PMID: 265910010.1182/blood.V73.8.2086.2086)
Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1997;20:745–52. (PMID: 10.1038/sj.bmt.1700963)
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71. (PMID: 1208675910.1016/S0140-6736(02)08938-9)
Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:971–83. (PMID: 10.1016/j.bbmt.2015.02.022)
André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. J Clin Oncol. 1999;17:222–9. (PMID: 1045823710.1200/JCO.1999.17.1.222)
Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP. et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease [published correction appears in J Clin Oncol. 1992 Jan;10(1):170]. J Clin Oncol. 1991;9:1871–9. (PMID: 191963710.1200/JCO.1991.9.10.1871)
Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, et al. Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transpl. 1998;22:265–71. (PMID: 10.1038/sj.bmt.1701325)
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW. et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801–13. (PMID: 902831110.1182/blood.V89.3.801)
Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernández JM, et al. Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transpl. 2000;25:31–4. (PMID: 10.1038/sj.bmt.1702094)
Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411.
Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17:825–31. (PMID: 1007127310.1200/JCO.1999.17.3.825)
Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transpl. 1997;20:21–6. (PMID: 10.1038/sj.bmt.1700838)
Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, United Kingdom Children’s Cancer Study Group. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26:740–5. (PMID: 1554300910.1097/00043426-200411000-00010)
Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transpl. 2004;33:1015–23. (PMID: 10.1038/sj.bmt.1704483)
Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–1404. (PMID: 1123048410.1200/JCO.2001.19.5.1395)
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106:1473–1478. (PMID: 1587018010.1182/blood-2004-12-4689)
Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli U, Falk RS, Fluge Ø. et al. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica. 2015;100:e240–e243. (PMID: 25682605445063910.3324/haematol.2014.119214)
Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61:579–86. (PMID: 2450479010.1002/pbc.24851)
Garfin PM, Link MP, Donaldson SS, Advani RH, Luna-Fineman S, Kharbanda S, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transpl. 2015;21:326–34. (PMID: 10.1016/j.bbmt.2014.10.020)
Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22:4532–40. (PMID: 1554280410.1200/JCO.2004.02.121)
Chen Y, Lane A, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046–53. (PMID: 10.1016/j.bbmt.2015.02.005)
Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–95. (PMID: 10.3324/haematol.2012.072090)
Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin’s disease. Br J Haematol. 2004;125:701–8. (PMID: 1518085910.1111/j.1365-2141.2004.04964.x)
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33. (PMID: 970473510.1200/JCO.1998.16.8.2825)
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V. et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–6. (PMID: 1113374810.1182/blood.V97.1.101)
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454–63. (PMID: 2823658310.1016/S1470-2045(17)30103-1)
Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classical Hodgkin disease. Cancer. 2003;98:310–4. (PMID: 1287235010.1002/cncr.11511)
Newcom SR, Kadin ME, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin’s cells arise from a single cloned mononuclear cell. Int J Cell Cloning. 1988;6:417–31. (PMID: 323032910.1002/stem.5530060606)
Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, et al. Circulating clonotypic B cells in classical Hodgkin lymphoma. Blood 2009;113:5920–6. (PMID: 19188663270032710.1182/blood-2008-11-189688)
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13(Sep):1356–63. (PMID: 1219636010.1093/annonc/mdf256)
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. (PMID: 251137712511377110.1200/JCO.2013.53.5229)
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32:3059–68. (PMID: 251137532511375310.1200/JCO.2013.54.8800)
Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, et al. T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects. J Clin Oncol. 2021;39:1415–25. (PMID: 3350780310.1200/JCO.20.02224)
Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798–808. (PMID: 2434422010.1200/JCO.2013.51.5304)
Jagadeesh D, Majhail NS, Ye, H. et al. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020;126:2279–87. (PMID: 3204935910.1002/cncr.32752)
Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transpl. 2002;29:769–75. (PMID: 10.1038/sj.bmt.1703515)
Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166–75. (PMID: 1849065010.1200/JCO.2007.14.4204)
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl J Med. 2015;372:311–9. (PMID: 2548223910.1056/NEJMoa1411087)
Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4:47–54. (PMID: 31899797696045710.1182/bloodadvances.2019000736)
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of Pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125–32. (PMID: 28441111579184310.1200/JCO.2016.72.1316)
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal Phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9. (PMID: 22454421364631610.1200/JCO.2011.38.0410)
Keilholz U, Szelényi H, Siehl J, Foss HD, Knauf W, Thiel E, et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin’s disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Leuk Lymphoma. 1999;35:641–2. (PMID: 1060980610.1080/10428199909169633)
Al-Ali HK, Wittekind C, Niederwieser D. Complete remission of relapsed mixed cellularity Hodgkin’s disease treated with rituximab. Dtsch Med Wochenschr. 2007;132:1688–91. (PMID: 1771386410.1055/s-2007-984950)
Gordon LI, Longnecker R. Off-targeting oft-targeted CD20 in cHL. Blood 2012;119:4095–6. (PMID: 2255565810.1182/blood-2012-03-413146)
Santos MAO, Lima M, de M, Santos MAO, Lima M, de M. CD20 role in pathophysiology of Hodgkin’s disease. Rev da Assocção Médica Brasileira. 2017;63:810–3. (PMID: 10.1590/1806-9282.63.09.810)
Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2013;31:256–62. (PMID: 2304559310.1200/JCO.2011.39.9881)
Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S. et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885–93. (PMID: 1924656110.1182/blood-2008-08-175208)
Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:1039–50. (PMID: 22228637328832410.1158/1078-0432.CCR-11-1429)
Farruggia P, Puccio G, Locatelli F, Vetro M, Pillon M, Trizzino A, et al. Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience. Leuk Lymphoma. 2019;60:696–702. (PMID: 3030143610.1080/10428194.2018.1493732)
Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD. et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116:4934–7. (PMID: 20733154379920410.1182/blood-2010-05-282756)
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28:1896–903. (PMID: 20212248365160110.1200/JCO.2009.26.5942)
Hutchings M, Radford J, Ansell SM, Illés Á, Sureda A, Connors JM, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol. 2021;39:185–95. (PMID: 33462822824788410.1002/hon.2838)
Keeping S, Wu E, Chan K, Mojebi A, Ferrante SA, Balakumaran A, et al. Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin’s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert Rev Hematol. 2018;11:503–11. (PMID: 2976424510.1080/17474086.2018.1475226)
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–62. (PMID: 2579645910.1016/S0140-6736(15)60165-9)
Edelmann J, Dokal AD, Vilventhraraja E, Holzmann K, Britton D, Klymenko T, et al. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. iScience. 2021;24:102089. (PMID: 33615197787899210.1016/j.isci.2021.102089)
Gamboa-Cedeño AM, Díaz M, Cristaldo N, Cristaldo N, Otero V, Schutz N, et al. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. Life Sci. 2021;268:118979. (PMID: 3342152810.1016/j.lfs.2020.118979)
Sawalha Y, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D, et al. Is rituximab sub-optimally dosed in indolent B cell lymphoma? Br J Haematol. 2016;174:721–9. (PMID: 2713633110.1111/bjh.14114)
Granot N, Rezvani AR, Pender BS, Storer BE, Sandmaier BM, Storb R, et al. Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biol Blood Marrow Transplant. 2020;26:1811–18. (PMID: 32693210754940310.1016/j.bbmt.2020.07.014)
Ha VH, Ghosh S, Leyshon C, Ryan N, Chambers CR, Stewart DA. Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. J Oncol Pharm Pr. 2018;24:323–31. (PMID: 10.1177/1078155217702214)
McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, et al. Association of Rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open. 2021;4:e2036321. (PMID: 33533931785984210.1001/jamanetworkopen.2020.36321)
Witzens-Harig M, Foá R, Di Rocco A, van Hazel G, Chamone DFA, Rowe JM, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014;93:1717–24. (PMID: 2482476810.1007/s00277-014-2103-3)
المشرفين على المادة: 04079A1RDZ (Cytarabine)
4F4X42SYQ6 (Rituximab)
Q41OR9510P (Melphalan)
U68WG3173Y (Carmustine)
تواريخ الأحداث: Date Created: 20220202 Date Completed: 20220412 Latest Revision: 20220530
رمز التحديث: 20221213
DOI: 10.1038/s41409-022-01599-5
PMID: 35105965
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5365
DOI:10.1038/s41409-022-01599-5